Identifying a Biomarker for Anti-angiogenic Therapy in Ovarian Cancer
Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian Cancer
This study is trying to see if a new marker called Multimerin-2 can help predict how well anti-angiogenic therapy works for women with advanced ovarian cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Centro di Riferimento Oncologico - Aviano Academic / other |
| Locations | 1 site (Aviano) |
| Trial ID | NCT05874115 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a biomarker, Multimerin-2, to predict the efficacy of anti-angiogenic therapy in patients with epithelial ovarian cancer (EOC). The study will analyze tumor tissue samples and biological fluids from female patients diagnosed with advanced stages of EOC to assess the relationship between Multimerin-2 levels and treatment outcomes. By understanding how Multimerin-2 influences drug delivery and resistance to therapy, the researchers hope to improve patient selection for this costly treatment. The study will utilize liquid biopsy techniques to gather necessary data.
Who should consider this trial
Good fit: Ideal candidates include female patients aged 18 and older with advanced-stage epithelial ovarian cancer who can provide tumor tissue samples.
Not a fit: Patients with low malignant potential ovarian tumors or those with other malignancies within the last five years may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enable more personalized treatment approaches for ovarian cancer patients, improving their chances of responding to anti-angiogenic therapies.
How similar studies have performed: While the approach of identifying biomarkers for treatment efficacy is common, the specific focus on Multimerin-2 in ovarian cancer is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Female patients aged ≥18 years 2. Histological diagnosis of epithelial carcinoma of the ovary or fallopian tubes or primary carcinoma of the peritoneum, including mixed Mullerian tumours. 3. Stage IIIb, IIIc or IV 4. Performance Status 0-2 according to ECOG 5. Availability of tumor tissue samples and biological fluids for molecular analyses 6. Informed consent for the collection, storage and use of biological material for the CRO Biobank (as specified in the consent of the CRO Biobank, Rev 2 of 03/10/2016), signed and obtained before surgery for suspected EOC. Exclusion Criteria: 1. Ovarian tumors of low malignant potential (i.e. borderline tumors) 2. Other malignacies within the last 5 years except carcinoma in situ of the cervix or early stage squamous cell or basal cell carcinoma of the skin, as long as they are adequately treated. 3. Active infection or uncontrolled chronic inflammatory disease
Where this trial is running
Aviano
- Centro di Riferimento Oncologico (CRO), IRCCS — Aviano, Italy (Recruiting)
Study contacts
- Principal investigator: Maurizio Maurizio — Centro di Riferimento Oncologico (CRO), IRCCS
- Study coordinator: Maurizio Maurizio
- Email: mmongiat@cro.it
- Phone: +390434659516
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.